BR0116084A - Amidas de ácido furanocarboxìlico e tiofenocarboxìlico ariladas com efeito bloqueador de canal de potássio - Google Patents

Amidas de ácido furanocarboxìlico e tiofenocarboxìlico ariladas com efeito bloqueador de canal de potássio

Info

Publication number
BR0116084A
BR0116084A BR0116084-2A BR0116084A BR0116084A BR 0116084 A BR0116084 A BR 0116084A BR 0116084 A BR0116084 A BR 0116084A BR 0116084 A BR0116084 A BR 0116084A
Authority
BR
Brazil
Prior art keywords
acid amides
atrial
arylated
potassium channel
furanecarboxylic
Prior art date
Application number
BR0116084-2A
Other languages
English (en)
Inventor
Stefan Peukert
Joachim Brendel
Horst Hemmerle
Heinz-Werner Kleemann
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of BR0116084A publication Critical patent/BR0116084A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"AMIDAS DE áCIDO FURANOCARBOXìLICO E TIOFENOCARBOXìLICO ARILADAS COM EFEITO BLOQUEADOR DE CANAL DE POTáSSIO". Amidas de ácido furanocarboxílico e tiofenocarboxílico ariladas, processo para sua preparação, seu emprego como medicamento, assim como preparados farmacêuticos contendo-as. Compostos de fórmula (Ia) e (Ib) nas quais X, R(1), R(2), R(3), R(4), R(5), R(6), R(7), e R(30) e R(31) têm os significados indicados nas reivindicações, são muito particularmente apropriados como substâncias ativas anti-arrítmicas novas, particularmente para tratamento e profilaxia de arritmias do átrio, por exemplo, vibração atrial (fibrilação atrial, AF) ou instabilidade atrial (instabilidade do átrio).
BR0116084-2A 2000-12-12 2001-11-29 Amidas de ácido furanocarboxìlico e tiofenocarboxìlico ariladas com efeito bloqueador de canal de potássio BR0116084A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10061876A DE10061876A1 (de) 2000-12-12 2000-12-12 Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
PCT/EP2001/013958 WO2002048131A1 (de) 2000-12-12 2001-11-29 Arylierte furan- und thiophencarbonsäureamide mit kalium kanal blockierender wirkung

Publications (1)

Publication Number Publication Date
BR0116084A true BR0116084A (pt) 2003-10-14

Family

ID=7666837

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116084-2A BR0116084A (pt) 2000-12-12 2001-11-29 Amidas de ácido furanocarboxìlico e tiofenocarboxìlico ariladas com efeito bloqueador de canal de potássio

Country Status (30)

Country Link
US (1) US6982279B2 (pt)
EP (1) EP1349846B1 (pt)
JP (1) JP4252798B2 (pt)
KR (1) KR20030061846A (pt)
CN (1) CN1225463C (pt)
AR (1) AR032781A1 (pt)
AT (1) ATE288906T1 (pt)
AU (2) AU2002235743B2 (pt)
BR (1) BR0116084A (pt)
CA (1) CA2431095A1 (pt)
CZ (1) CZ20031633A3 (pt)
DE (2) DE10061876A1 (pt)
DK (1) DK1349846T3 (pt)
EE (1) EE05306B1 (pt)
ES (1) ES2236335T3 (pt)
HK (1) HK1061850A1 (pt)
HR (1) HRP20030469A2 (pt)
HU (1) HUP0303665A3 (pt)
IL (2) IL156314A0 (pt)
MX (1) MXPA03004770A (pt)
NO (1) NO329163B1 (pt)
NZ (1) NZ526383A (pt)
PL (1) PL362410A1 (pt)
PT (1) PT1349846E (pt)
RS (1) RS50336B (pt)
RU (1) RU2275366C2 (pt)
SK (1) SK287464B6 (pt)
TW (1) TWI288134B (pt)
WO (1) WO2002048131A1 (pt)
ZA (1) ZA200304091B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
JP4544857B2 (ja) * 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Flavivirus感染の治療または予防のための化合物および方法
US7402608B2 (en) * 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1493739A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
KR20080016597A (ko) * 2005-05-13 2008-02-21 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법
US8278317B2 (en) * 2005-07-22 2012-10-02 Merck Sharp & Dohme Corp. Potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
CN101636154B (zh) * 2006-04-27 2011-12-14 塞诺菲-安万特德国有限公司 Task-1和task-3离子通道抑制剂
KR20090086081A (ko) * 2006-11-15 2009-08-10 바이로켐 파마 인코포레이티드 플라비바이러스 감염의 치료 또는 예방용 티오펜 유사체
US8263641B2 (en) 2007-09-10 2012-09-11 Calcimedica, Inc. Compounds that modulate intracellular calcium
ITMI20071971A1 (it) * 2007-10-10 2009-04-11 Altergon Sa Composizione farmaceutica per la somministrazione sublinguale di progesterone, e metodo per la sua preparazione
US8389567B2 (en) 2007-12-12 2013-03-05 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN102256969A (zh) 2008-08-27 2011-11-23 钙医学公司 调节胞内钙的化合物
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
US8524763B2 (en) 2008-09-22 2013-09-03 Calcimedica, Inc. Inhibitors of store operated calcium release
US8143269B2 (en) 2008-10-03 2012-03-27 Calcimedica, Inc. Inhibitors of store operated calcium release
PE20120003A1 (es) * 2009-01-30 2012-02-12 Glaxosmithkline Llc Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil)etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino
US8618307B2 (en) 2009-09-16 2013-12-31 Calcimedica, Inc. Compounds that modulate intracellular calcium
MX2012014273A (es) 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
CA2809830C (en) 2010-08-27 2019-09-10 Calcimedica, Inc. Compounds comprising n-acyl-2-amino-1,3-thiazole for modulating intracellular calcium
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (pt) 2011-07-01 2018-04-28
NZ627942A (en) 2012-01-27 2016-03-31 Gilead Sciences Inc Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN103012381B (zh) * 2013-01-10 2015-01-07 山东大学 苯基呋喃类化合物、其制备方法及在制备抗心律失常药物中的应用
KR101721490B1 (ko) * 2014-07-30 2017-03-30 한국생명공학연구원 페닐 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 세포증식성 질병의 예방 또는 치료용 약학적 조성물
EP3366683A1 (en) * 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214120D0 (en) * 1991-07-25 1992-08-12 Ici Plc Therapeutic amides
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
IL109570A0 (en) * 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US6013664A (en) * 1996-11-27 2000-01-11 Bayer Aktiengesellschaft Microbicidal agents based on thiophene-2-carboxylic acid derivatives
CN1265643A (zh) * 1997-08-05 2000-09-06 美国家用产品公司 邻氨基苯甲酸类似物
CA2315070A1 (en) * 1997-12-17 1999-07-01 Schering Aktiengesellschaft Ortho-anthranilamide derivatives as anti-coagulants
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
WO1999041231A1 (fr) * 1998-02-17 1999-08-19 Ono Pharmaceutical Co., Ltd. Derives amidino utilises comme ingredients actifs et medicaments les contenant
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
EP1082315A1 (en) 1998-06-05 2001-03-14 Icagen, Inc. Potassium channel inhibitors
AU754204B2 (en) 1998-09-01 2002-11-07 Bristol-Myers Squibb Company Potassium channel inhibitors and method
AU5379900A (en) * 1999-06-07 2000-12-28 Shire Biochem Inc. Thiophene integrin inhibitors
EP1419161A1 (en) * 2001-08-24 2004-05-19 PHARMACIA & UPJOHN COMPANY Substituted-heteroaryl-7-aza 2.2.1]bicycloheptanes for the treatment of disease

Also Published As

Publication number Publication date
US20040068120A1 (en) 2004-04-08
AU3574302A (en) 2002-06-24
EP1349846B1 (de) 2005-02-09
CA2431095A1 (en) 2002-06-20
HUP0303665A2 (hu) 2004-03-01
KR20030061846A (ko) 2003-07-22
WO2002048131A1 (de) 2002-06-20
EE200300240A (et) 2003-08-15
TWI288134B (en) 2007-10-11
RU2275366C2 (ru) 2006-04-27
EE05306B1 (et) 2010-06-15
HK1061850A1 (en) 2004-10-08
NO20032535L (no) 2003-07-29
IL156314A (en) 2008-12-29
AR032781A1 (es) 2003-11-26
AU2002235743B2 (en) 2006-07-20
DE50105337D1 (de) 2005-03-17
CZ20031633A3 (cs) 2003-08-13
ATE288906T1 (de) 2005-02-15
PL362410A1 (en) 2004-11-02
RS50336B (sr) 2009-11-10
NO20032535D0 (no) 2003-06-04
HRP20030469A2 (en) 2005-04-30
MXPA03004770A (es) 2003-09-10
DE10061876A1 (de) 2002-06-20
SK287464B6 (sk) 2010-10-07
US6982279B2 (en) 2006-01-03
EP1349846A1 (de) 2003-10-08
ZA200304091B (en) 2004-04-23
YU42503A (sh) 2006-05-25
JP4252798B2 (ja) 2009-04-08
ES2236335T3 (es) 2005-07-16
SK7252003A3 (en) 2003-12-02
NO329163B1 (no) 2010-08-30
CN1479734A (zh) 2004-03-03
CN1225463C (zh) 2005-11-02
HUP0303665A3 (en) 2005-02-28
NZ526383A (en) 2004-11-26
PT1349846E (pt) 2005-05-31
DK1349846T3 (da) 2005-05-30
IL156314A0 (en) 2004-01-04
JP2004526680A (ja) 2004-09-02

Similar Documents

Publication Publication Date Title
BR0116084A (pt) Amidas de ácido furanocarboxìlico e tiofenocarboxìlico ariladas com efeito bloqueador de canal de potássio
BR0116005A (pt) Compostos de bisarila nìtricos, orto-substituìdos, para uso como inibidores de canal de potássio
BR0017050A (pt) Oxazolidinonas suebstituìdas e seu emprego na área da coagulação do sangue
BRPI9810519A (pt) derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
ES2133785T3 (es) Inhibidores de metaloproteinasas.
BR0008840A (pt) Derivados de camptotecina tendo atividade antitumoral
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BR0200782A (pt) Compostos para o tratamento da isquemia
BR0014465A (pt) 1,1'-bifenil-2-carbonamidas 2'-substituìdas, processos para a sua preparação,seu emprego como medicamento bem como os preparados farmacêuticos contendo as mesmas
BR9916192A (pt) Formulações agroquìmicas
SE8804629D0 (sv) New therapeutically active compounds
TR200103701T2 (tr) İndanil ikameli benzolkarbonamidleri, imalat yöntemleri, ilaç olarak kullanımları
BRPI9914741A (pt) n-(2-aril-proprionil)-sulfonamidas, usos e composições farmacêuticas contendo as mesmas.
BR0014384A (pt) Compostos para o tratamento da isquémia
BR0108893A (pt) Composição farmacêutica, composto e processo de preparação de compostos
BR0316234A (pt) Hidroxiindóis, seu uso como inibidores de fosfodiesterase 4 e processos para a preparação dos mesmos
BR9806870A (pt) Composto, processo para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, formulação farmacêutica, e, uso de um composto e processo para preparar o mesmo.
EA200200571A1 (ru) Новая композиция и ее применение
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
NO883229L (no) Nye benzimidazolderivater, fremgangsmaate for deres fremstilling og farmasoeytisk preparat inneholdende slike derivater.
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
BR9801150A (pt) Derivados de propanolamina, processos para a preparação deles, produtos farmacêuticos compreendendo esses compostos e uso dos mesmos.
BR0115883A (pt) Derivados de ácido amino-furan-2-il-acético e ácido amino-tien-2-il-acético substituìdos e seu emprego para o tratamento de cefaléia ou dor
BR9913982A (pt) Derivado de piridil-4h-1,2,4-oxadiazina opticamente ativo e seu uso no tratamento de doenças vasculares

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.